A Valif 20 mg offer is not ready for a wholesale order until you verify its UK supply route, exact product identity, batch records and clinical documentation. By the end, you will have a practical checklist for comparing suppliers, deciding whether the 20 mg strength fits the intended market, and protecting patients from unsuitable or falsified medicines.
Key takeaways
- Confirm a UK marketing authorisation or documented legal supply route.
- Request the supplier’s MHRA wholesale distribution authorisation and batch certificate.
- Compare vardenafil strength, formulation, registration status and traceability—not brand name alone.
- Reject 20 mg when contraindications, interacting medicines or patient-specific risks apply.
Is Valif 20 mg lawful for wholesale supply in England?
Vardenafil is a prescription-only medicine in the UK, so a Valif 20 mg offer is not a lawful wholesale transaction merely because the tablets are manufactured in India or labelled for export. Confirm the exact product has a current UK marketing authorisation, a parallel import licence, or another documented legal supply route.
A product marketed in India is not automatically authorised for sale in England.
Before ordering, require written evidence that:
- The active ingredient is vardenafil, the strength is 20 mg, and the dosage form, manufacturer, pack size and leaflet match the offered product.
- The supplier and import route are authorised for the proposed transaction, with MHRA registration or licensing where applicable, and the recipient is permitted to receive prescription medicines.
- The batch has traceable release evidence, including its batch number, certificate of analysis, manufacturing and expiry dates, product specification and packaging records.
- Storage and transport follow Good Distribution Practice, with temperature records, tamper-evident packaging, recall contacts, complaint handling and suspected-falsified-medicine procedures.
- The invoice, packing list and export documents identify the same product, manufacturer and batch.
A Certificate of Pharmaceutical Product, WHO-GMP certificate or export approval supports quality assessment; none alone proves UK marketing authorisation. Reject offers aimed at direct consumer sale, missing traceability, or vague claims that “Valif” itself establishes legality. A low price does not cure an unauthorised supply route.
How do you verify the supplier and its batch documents?
A legitimate vardenafil tablet supplier uk must identify the exact Valif product, strength, tablet form, pack size and manufacturer. Check that combination against a current UK marketing authorisation or another lawful UK supply basis; an Indian Certificate of Pharmaceutical Product, WHO-GMP certificate or export approval alone does not authorise routine sale in England.
For imports from India, verify the authorised manufacturer or importer, UK-qualified-person certification and the distribution route.
Request these records before ordering:
- MHRA licence or registration details for the manufacturer, importer or wholesaler, where applicable, plus the manufacturing site address and GMP evidence.
- The batch number, certificate of analysis, product specification, manufacturing date, expiry date, package insert and tamper-evident packaging description.
- Manufacturing and packaging records, or equivalent batch-release evidence, plus stability data supporting the stated shelf life.
- Invoice, packing list, export documents, temperature records and transport conditions for the shipment.
- GDP procedures covering approved suppliers, traceability, complaints, recalls, returned goods and suspected falsified medicines.
| Document | What it proves | Stop if missing |
|---|---|---|
| UK authorisation record | The exact product and strength have a lawful UK supply basis | The record covers another manufacturer, strength or dosage form |
| Importer and QP evidence | The India-to-England import and release route is controlled | The exporter cannot identify the importer or certifying QP |
| Batch records and traceability | This shipment matches the tested, released batch | The certificate of analysis has no matching batch number |
A low price does not offset missing release evidence, temperature history or recall contacts. Do not treat a certificate of analysis alone as proof of lawful distribution.
How should you compare branded Valif, generic vardenafil and the 20 mg specification?
Treat the brand name as an identifier, not a quality test. For a valif tablet wholesale supply, match the offered pack against its active ingredient, 20 mg strength, tablet formulation, manufacturer, approved presentation and UK regulatory status.
Check the exact pack and authorisation details in the MHRA medicines register; an Indian-market product is not automatically authorised for sale in England.
| Option | What to verify | Decision |
|---|---|---|
| Branded Valif | Manufacturer, authorisation holder, product number, pack size, leaflet and current status | Accept only when the exact presentation is lawful and documented |
| Authorised generic vardenafil | Vardenafil strength, dosage form, excipients, manufacturer, bioequivalence or authorisation evidence and patient information | Compare as its own authorised product, not as Valif by another name |
| “20 mg” specification alone | Batch number, composition, packaging, expiry, storage requirements and regulatory route | Reject the assumption that every 20 mg tablet is interchangeable |
Put the agreed specification into the purchase order, including minimum order quantity, remaining shelf life on delivery, Incoterms, controlled-storage conditions, transit-damage replacement and responsibility for UK regulatory release. NIBA HEALTHCARE should be asked to identify whether its quotation is for branded Valif or a generic product and provide documents matching that choice.
A certificate of analysis alone does not prove product identity, lawful distribution or Good Distribution Practice controls.
Related product
![]() | VARDENAFIL TABLET 20MG Valif 20 Tablet is used to treat erectile dysfunction in men. It increases blood flow to the penis to help men get an erection. View product → |
When is 20 mg unsuitable, and what dosing and interaction checks matter?
Twenty milligrams is the maximum vardenafil dose, not the routine starting dose. Prescribing information should direct the prescriber to consider 10 mg first, reduce to 5 mg for tolerability or risk factors, and use 20 mg only when a lower dose is effective but insufficient.
Take one tablet about 25 to 60 minutes before sexual activity, with sexual stimulation required for an effect. Do not take more than one dose in 24 hours. A high-fat meal can delay absorption, so retain the finished-product food instruction rather than replacing it with “take as directed”.
Do not supply 20 mg for patients taking any of the following:
- Organic nitrates or nitric-oxide donors, including glyceryl trinitrate, isosorbide medicines and recreational amyl nitrite (“poppers”)
- Riociguat
- Potent CYP3A4 inhibitors such as ritonavir or indinavir; ketoconazole, itraconazole, erythromycin and clarithromycin also require a prescriber’s dose review
- Alpha-blockers, unless the patient is stable and the prescriber has checked the starting dose and timing
A prescriber must assess cardiovascular fitness for sexual activity. Do not treat 20 mg as suitable for patients with unstable angina, severe heart failure, uncontrolled blood pressure, recent stroke or myocardial infarction, or serious uncontrolled arrhythmia. Review liver disease, kidney disease, QT-prolonging medicines and other cardiovascular treatment before dispensing.
What safety information must reach patients and healthcare professionals?
Before distribution, provide the approved patient information leaflet and Summary of Product Characteristics, not a shortened sales sheet. Patients need to know that headache, flushing, indigestion, nasal congestion and dizziness are recognised effects; healthcare professionals need the full interaction warnings, including nitrates or “poppers”, riociguat, QT prolongation, and class IA or III antiarrhythmics.
| Signal | Information to provide | Required response |
|---|---|---|
| Expected effects | Headache, flushing, dyspepsia, nasal congestion and dizziness | Give self-care advice and seek clinical review if persistent or severe |
| Emergency effects | Chest pain, fainting, seizure, sudden vision or hearing loss, severe allergic reaction, or an erection lasting more than four hours | Stop use and obtain urgent medical help; report the reaction through the Yellow Card scheme |
| Suspected falsification | Spelling errors, altered colours, broken seals, mismatched batch or expiry details, missing patient leaflet, or tablets that differ from the approved presentation | Do not supply or use; quarantine the stock and escalate it |
The supplier must show batch traceability from receipt to every customer, with documented complaint, return and recall procedures. A suspected falsified pack requires physical segregation, an investigation against the purchase and delivery records, prompt notification to the MHRA, and preservation of samples and packaging.
Record adverse-event reports, retain the affected batch details, and give healthcare professionals a named contact for follow-up. A certificate of analysis alone does not prove these controls.
Frequently asked questions
Is Valif 20 mg lawful for wholesale supply in England?
Vardenafil is prescription-only in the UK. Confirm a current UK marketing authorisation, parallel import licence or another documented legal supply route before buying.
How do you verify a Valif supplier and its batch documents?
Check the supplier’s MHRA wholesale distribution authorisation, manufacturer details, product registration and batch records, including the certificate of analysis and expiry date.
How should you compare branded Valif, generic vardenafil and the 20 mg specification?
Compare the active ingredient, strength, pharmaceutical form, registration status, packaging, manufacturer, storage instructions and complete batch traceability.
When is vardenafil 20 mg unsuitable?
A prescriber must assess cardiovascular status, contraindications, dose limits, renal or hepatic impairment and interactions, especially nitrates and riociguat.
What safety information must reach patients and healthcare professionals?
Provide the authorised product information, dosing instructions, contraindications, interaction warnings, storage details and urgent advice for priapism, sudden vision loss or chest pain.
